HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
ADDERALL XR safely and effectively. See full prescribing
information for ADDERALL XR.
ADDERALL XR
®
(mixed salts of a single-entity amphetamine
product) extended-release capsules, for oral use, CII
Initial U.S. Approval: 2001
WARNING: ABUSE, MISUSE, AND ADDICTION
See full prescribing information for complete boxed warning.
ADDERALL XR has a high potential for abuse and misuse,
which can lead to the development of a substance use
disorder, including addiction. Misuse and abuse of CNS
stimulants, including ADDERALL XR, can result in overdose
and death (5.1, 9.2, 10):
• Before prescribing ADDERALL XR, assess each patient’s
risk for abuse, misuse, and addiction.
• Educate patients and their families about these risks,
proper storage of the drug, and proper disposal of any
unused drug.
• Throughout treatment, reassess each patient’s risk and
frequently monitor for signs and symptoms of abuse,
misuse, and addiction.
--------------------------RECENT MAJOR CHANGES----------------------------
Boxed Warning 10/2023
Indications and Usage (1) 10/2023
Dosage and Administration (2.1, 2.2, 2.7) 10/2023
Contraindications (4) 10/2023
Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.7, 5.9) 10/2023
-------------------------INDICATIONS AND USAGE------------------------------
ADDERALL XR, a CNS stimulant, is indicated for the treatment of
attention deficit hyperactivity disorder (ADHD) in adults and pediatric
patients 6 years and older. (1)
---------------------------DOSAGE AND ADMINISTRATION-------------------
• Pediatric patients (ages 6 to 17): 10 mg once daily in the morning.
Maximum dose for children 6 to 12 years of age is 30 mg once
daily. (2.2, 2.3, 2.4)
• Adults: 20 mg once daily in the morning. (2.5)
• Pediatric patients (ages 6 to 17) with severe renal impairment:
5 mg once daily in the morning. Maximum dose for children 6 to
12 years of age with severe renal impairment is 20 mg once daily.
(2.6, 8.6)
• Adults with severe renal impairment: 15 mg once daily in the
morning. (2.6, 8.6)
• Patients with ESRD: Not recommended. (2.6, 8.6)
-----------------------DOSAGE FORMS AND STRENGTHS--------------------
Extended-release capsules: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg,
30 mg (3)
------------------------------CONTRAINDICATIONS----------------------------
• Known hypersensitivity or idiosyncrasy to amphetamine (4)
• During or within 14 days following the administration of monoamine
oxidase inhibitors (MAOI) (4, 7.1)
--------------------------WARNINGS AND PRECAUTIONS---------------------
• Risks to Patients with Serious Cardiac Disease: Avoid use in
patients with known structural cardiac abnormalities,
cardiomyopathy, serious cardiac arrhythmias, coronary artery
disease, or other serious cardiac disease. (5.2)
• Increased Blood Pressure and Heart Rate: Monitor blood pressure
and pulse at appropriate intervals. (5.3)
• Psychiatric Adverse Reactions: Prior to initiating ADDERALL XR,
screen patients for risk factors for developing a manic episode. If
new psychotic or manic symptoms occur, consider discontinuing
ADDERALL XR. (5.4)
• Long-Term Suppression of Growth in Pediatric Patients: Closely
monitor growth (height and weight) in pediatric patients. Pediatric
patients not growing or gaining height or weight as expected may
need to have their treatment interrupted. (5.5)
• Seizures: May lower the convulsive threshold. Discontinue in the
presence of seizures. (5.6)
• Peripheral Vasculopathy, Including Raynaud’s Phenomenon:
Careful observation for digital changes is necessary during
ADDERALL XR treatment. Further clinical evaluation (e.g.,
rheumatology referral) may be appropriate for patients who develop
signs or symptoms of peripheral vasculopathy. (5.7)
• Serotonin Syndrome: Increased risk when coadministered with
serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during
overdosage situations. If it occurs, discontinue ADDERALL XR and
initiate supportive treatment. (4, 5.8, 10)
• Motor and Verbal Tics, and Worsening of Tourette’s Syndrome:
Before initiating ADDERALL XR, assess the family history and
clinically evaluate patients for tics or Tourette’s syndrome.
Regularly monitor patients for the emergence or worsening of tics
or Tourette’s syndrome. Discontinue treatment if clinically
appropriate. (5.9)
--------------------------------ADVERSE REACTIONS-----------------------------
• Pediatric patients ages 6 to 12: Most common adverse reactions
(≥5% and with a higher incidence than on placebo) were loss of
appetite, insomnia, abdominal pain, emotional lability, vomiting,
nervousness, nausea, and fever. (6.1)
• Pediatric patients ages 13 to 17: Most common adverse reactions
(≥5% and with a higher incidence than on placebo) were loss of
appetite, insomnia, abdominal pain, weight loss, and nervousness.
(6.1)
• Adults: Most common adverse reactions ≥5% and with a higher
incidence than on placebo were dry mouth, loss of appetite,
insomnia, headache, weight loss, nausea, anxiety, agitation,
dizziness, tachycardia, diarrhea, asthenia, and urinary tract
infections. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Takeda
Pharmaceuticals at 1-800-828-2088 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
--------------------------------DRUG INTERACTIONS------- ----------------------
• Alkalinizing agents (GI antacids and urinary): These agents
increase blood levels of amphetamine. (2.7, 7.1)
• Acidifying agents (GI and urinary): These agents reduce blood
levels of amphetamine. (7.1)
--------------------------USE IN SPECIFIC POPULATIONS---------------------
• Pregnancy: May cause fetal harm. (8.1)
• Lactation: Breastfeeding not recommended. (8.2)
See 17 for PATIENT COUNSELING INFORMATION and Medication
Guide.
Revised: 10/2023
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 2 of 21
FULL PRESCRIBING INFORMATION: CONTENTS*
7 DRUG INTERACTIONS
7.1 Clinically Important Interactions with Amphetamines
7.2 Drug-Laboratory Test Interactions
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
9 DRUG ABUSE AND DEPENDENCE
9.1 Controlled Substance
9.2 Abuse
9.3 Dependence
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2 Animal Toxicology and/or Pharmacology
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
* Sections or subsections omitted from the full prescribing
information are not listed.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 3 of 21
FULL PRESCRIBING INFORMATION
WARNING: ABUSE, MISUSE, AND ADDICTION
ADDERALL XR has a high potential for abuse and misuse, which can lead to the development
of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants,
including ADDERALL XR, can result in overdose and death [see Overdosage (10)], and this
risk is increased with higher doses or unapproved methods of administration, such as
snorting or injection.
Before prescribing ADDERALL XR, assess each patient’s risk for abuse, misuse, and
addiction. Educate patients and their families about these risks, proper storage of the drug,
and proper disposal of any unused drug. Throughout ADDERALL XR treatment, reassess each
patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms
of abuse, misuse, and addiction [see Warnings and Precautions (5.1), Drug Abuse and
Dependence (9.2)].
1 INDICATIONS AND USAGE
1.1 Attention Deficit Hyperactivity Disorder
ADDERALL XR
®
is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in
adults and pediatric patients 6 years and older.
2 DOSAGE AND ADMINISTRATION
2.1 Pretreatment Screening
Prior to treating patients with ADDERALL XR, assess:
• for the presence of cardiac disease (i.e., perform a careful history, family history of sudden
death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions (5.2)].
• the family history and clinically evaluate patients for motor or verbal tics or Tourette’s
syndrome before initiating ADDERALL XR [see Warnings and Precautions (5.9)].
2.2 General Administration Information
Individualize the dosage according to the therapeutic needs and response of the patient. Administer
ADDERALL XR at the lowest effective dosage.
Based on bioequivalence data, patients taking divided doses of immediate-release ADDERALL,
(for
example, twice daily), may be switched to ADDERALL XR
at the same total daily dose taken once
daily. Titrate at weekly intervals to appropriate efficacy and tolerability as indicated.
ADDERALL XR extended-release capsules may be taken whole, or the capsule may be opened and
the entire contents sprinkled on applesauce. If the patient is using the sprinkle administration method,
the sprinkled applesauce should be consumed immediately; it should not be stored. Patients should
take the applesauce with sprinkled beads in its entirety without chewing. The dose of a single capsule
should not be divided. The contents of the entire capsule should be taken, and patients should not
take anything less than one capsule per day.
ADDERALL XR may be taken orally with or without food.
ADDERALL XR should be given upon awakening. Afternoon doses should be avoided because of the
potential for insomnia.
2.3 Recommended Dosage in Pediatric Patients 6 to 12 Years
In pediatric patients 6 to 12 years of age with ADHD and are either starting treatment for the first time
or switching from another medication, start with 10 mg once daily in the morning; daily dosage may
be adjusted in increments of 5 mg or 10 mg at weekly intervals. When in the judgment of the clinician
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 4 of 21
a lower initial dose is appropriate, patients may begin treatment with 5 mg once daily in the morning.
The maximum recommended dose for children 6 to 12 years of age is 30 mg/day; doses greater than
30 mg/day have not been studied in children. ADDERALL XR has not been studied in children under
6 years of age.
2.4 Recommended Dosage in Pediatric Patients 13 to 17 Years
The recommended starting dose for pediatric patients 13 to 17 years of age with ADHD and are either
starting treatment for the first time or switching from another medication is 10 mg/day. The dose may
be increased to 20 mg/day after one week if ADHD symptoms are not adequately controlled.
2.5 Recommended Dosage in Adults
In adults with ADHD who are either starting treatment for the first time or switching from another
medication, the recommended dose is 20 mg/day.
2.6 Dosage in Patients with Renal Impairment
In adult patients with severe renal impairment (GFR 15 to <30 mL/min/1.73 m
2
), the recommended
dose is 15 mg once daily in the morning. In pediatric patients (6 to 17 years of age) with severe renal
impairment, the recommended dose is 5 mg once daily. The maximum dose for children 6 to 12 years
of age with severe renal impairment is 20 mg once daily. ADDERALL XR is not recommended in
patients with end stage renal disease (ESRD) (GFR <15 mL/min/1.73 m
2
) [see Use in Specific
Populations (8.6), Clinical Pharmacology (12.3)].
2.7 Dosage Modification Due to Drug Interactions
Agents that alter urinary pH can impact excretion and alter blood levels of amphetamines. Acidifying
agents (e.g., ascorbic acid) decrease blood levels; adjust ADDERALL XR dosage based on clinical
response [see Drug Interactions (7)].
3 DOSAGE FORMS AND STRENGTHS
ADDERALL XR
5 mg extended-release capsules: Clear/blue (imprinted ADDERALL XR 5 mg)
ADDERALL XR
10 mg extended-release capsules: Blue/blue (imprinted ADDERALL XR 10 mg)
ADDERALL XR
15 mg extended-release capsules: Blue/white (imprinted ADDERALL XR 15 mg)
ADDERALL XR
20 mg extended-release capsules: Orange/orange (imprinted ADDERALL XR 20 mg)
ADDERALL XR
25 mg extended-release capsules: Orange/white (imprinted ADDERALL XR 25 mg)
ADDERALL XR
30 mg extended-release capsules: Natural/orange (imprinted ADDERALL XR 30 mg)
4 CONTRAINDICATIONS
ADDERALL XR administration is contraindicated in patients:
• known to be hypersensitive to amphetamine, or other components of ADDERALL XR.
Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported
in patients treated with other amphetamine products [see Adverse Reactions (6.2)].
• taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including
MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of
hypertensive crisis [see Warnings and Precautions (5.8), Drug Interactions (7.1)]
5 WARNINGS AND PRECAUTIONS
5.1 Abuse, Misuse, and Addiction
ADDERALL XR has a high potential for abuse and misuse. The use of ADDERALL XR exposes
individuals to the risks of abuse and misuse, which can lead to the development of a substance use
disorder, including addiction. ADDERALL XR can be diverted for non-medical use into illicit channels
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 5 of 21
or distribution [see Drug Abuse and Dependence (9.2)]. Misuse and abuse of CNS stimulants,
including ADDERALL XR, can result in overdose and death [see Overdosage (10)], and this risk is
increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing ADDERALL XR, assess each patient’s risk for abuse, misuse, and addiction.
Educate patients and their families about these risks and proper disposal of any unused drug. Advise
patients to store ADDERALL XR in a safe place, preferably locked, and instruct patients to not give
ADDERALL XR to anyone else. Throughout ADDERALL XR treatment, reassess each patient’s risk
of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse,
and addiction.
5.2 Risks to Patients with Serious Cardiac Disease
Sudden death has been reported in patients with structural cardiac abnormalities or other serious
cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage. Avoid
ADDERALL XR use in patients with known structural cardiac abnormalities, cardiomyopathy, serious
cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.
5.3 Increased Blood Pressure and Heart Rate
CNS stimulants may cause an increase in blood pressure (mean increase approximately 2 to
4 mmHg) and heart rate (mean increase approximately 3 to 6 bpm).
Monitor all ADDERALL XR-treated patients for hypertension and tachycardia.
5.4 Psychiatric Adverse Reactions
Exacerbation of Pre-Existing Psychosis
Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder
in patients with pre-existing psychotic disorder.
Induction of a Manic Episode in Patients with Bipolar Disease
CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating ADDERALL XR
treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of
depressive symptoms or a family history of suicide, bipolar disorder, or depression).
New Psychotic or Manic Symptoms
CNS stimulants, at the recommended dosage, may cause psychotic or manic symptoms (e.g.,
hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or
mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants,
psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients
compared to 0% of placebo-treated patients. If such symptoms occur, consider discontinuing
ADDERALL XR.
5.5 Long-Term Suppression of Growth in Pediatric Patients
CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric
patients. Closely monitor growth (weight and height) in ADDERALL XR-treated pediatric patients
treated with CNS stimulants.
In a controlled trial of ADDERALL XR in adolescents, mean weight change from baseline within the
initial 4 weeks of therapy was -1.1 lbs. and -2.8 lbs., respectively, for patients receiving 10 and 20 mg
ADDERALL XR. Higher doses were associated with greater weight loss within the initial 4 weeks of
treatment. Chronic use of amphetamines can be expected to cause a similar suppression of growth
[see Adverse Reactions (6.1)].
Pediatric patients who are not growing or gaining weight as expected may need to have their
treatment interrupted.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 6 of 21
5.6 Seizures
There is some clinical evidence that stimulants may lower the convulsive threshold in patients with
prior history of seizures, in patients with prior EEG abnormalities in the absence of seizures, and very
rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the
presence of seizures, ADDERALL XR should be discontinued.
5.7 Peripheral Vasculopathy, Including Raynaud’s Phenomenon
CNS stimulants, including ADDERALL XR, used to treat ADHD are associated with peripheral
vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and
mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of
peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports
and at the therapeutic dosage of CNS stimulants in all age groups throughout the course of
treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the
CNS stimulant.
Careful observation for digital changes is necessary during ADDERALL XR treatment. Further clinical
evaluation (e.g., rheumatology referral) may be appropriate for ADDERALL XR-treated patients who
develop signs or symptoms of peripheral vasculopathy.
5.8 Serotonin Syndrome
Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used
in combination with other drugs that affect the serotonergic neurotransmitter systems such as MAOIs,
selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs),
triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s
Wort [see Drug Interactions (7.1)]. Amphetamines and amphetamine derivatives are known to be
metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of
CYP2D6 metabolism [see Clinical Pharmacology (12.3)]. The potential for a pharmacokinetic
interaction exists with the coadministration of CYP2D6 inhibitors which may increase the risk with
increased exposure to ADDERALL XR. In these situations, consider an alternative nonserotonergic
drug or an alternative drug that does not inhibit CYP2D6 [see Drug Interactions (7.1)]. Serotonin
syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and
coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing,
hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia,
incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).
Concomitant use of ADDERALL XR with MAOI drugs is contraindicated [see Contraindications (4)].
Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if
symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. Concomitant
use of ADDERALL XR with other serotonergic drugs or CYP2D6 inhibitors should be used only if the
potential benefit justifies the potential risk. If clinically warranted, consider initiating ADDERALL XR
with lower doses, monitoring patients for the emergence of serotonin syndrome during drug initiation
or titration, and informing patients of the increased risk for serotonin syndrome.
5.9 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome
CNS stimulants, including amphetamine, have been associated with the onset or exacerbation of
motor and verbal tics. Worsening of Tourette’s syndrome has also been reported [see Adverse
Reactions (6.2)].
Before initiating ADDERALL XR, assess the family history and clinically evaluate patients for tics or
Tourette’s syndrome. Regularly monitor ADDERALL XR-treated patients for the emergence or
worsening of tics or Tourette’s syndrome, and discontinue treatment if clinically appropriate.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 7 of 21
6 ADVERSE REACTIONS
The following adverse reactions are discussed in greater detail in other sections of the labeling:
• Abuse, Misuse, and Addiction [see Boxed Warning, Warnings and Precautions (5.1), Drug
Abuse and Dependence (9.2, 9.3)]
• Risks to Patients with Serious Cardiac Disease [see Warnings and Precautions (5.2)]
• Increased Blood Pressure and Heart Rate [see Warnings and Precautions (5.3)]
• Psychiatric Adverse Reactions [see Warnings and Precautions (5.4)]
• Long-Term Suppression of Growth in Pediatric Patients [see Warnings and Precautions (5.5)]
• Seizures [see Warnings and Precautions (5.6)]
• Peripheral Vasculopathy, including Raynaud’s Phenomenon [see Warnings and Precautions
(5.7)]
• Serotonin Syndrome [see Warnings and Precautions (5.8)]
• Motor and Verbal Tics, and Worsening of Tourette’s Syndrome [see Warnings and Precautions
(5.9)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of
another drug and may not reflect the rates observed in practice.
The premarketing development program for ADDERALL XR included exposures in a total of
1,315 participants in clinical trials (635 pediatric patients, 350 adolescent patients, 248 adult patients,
and 82 healthy adult subjects). Of these, 635 patients (ages 6 to 12) were evaluated in two controlled
clinical studies, one open-label clinical study, and two single-dose clinical pharmacology studies
(N=40). Safety data on all patients are included in the discussion that follows. Adverse reactions were
assessed by collecting adverse reactions, results of physical examinations, vital signs, weights,
laboratory analyses, and ECGs.
Adverse reactions during exposure were obtained primarily by general inquiry and recorded by
clinical investigators using terminology of their own choosing. Consequently, it is not possible to
provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without
first grouping similar types of reactions into a smaller number of standardized event categories. In the
tables and listings that follow, COSTART terminology has been used to classify reported adverse
reactions.
The stated frequencies of adverse reactions represent the proportion of individuals who experienced,
at least once, a treatment-emergent adverse event of the type listed.
Adverse Reactions Leading to Discontinuation of Treatment
In two placebo-controlled studies of up to 5 weeks duration among children with ADHD, 2.4%
(10/425) of ADDERALL XR-treated patients discontinued due to adverse reactions (including three
patients with loss of appetite, one of whom also reported insomnia) compared to 2.7% (7/259)
receiving placebo.
The most frequent adverse reactions leading to discontinuation of ADDERALL XR in controlled and
uncontrolled, multiple-dose clinical trials of children (N=595) were anorexia (loss of appetite) (2.9%),
insomnia (1.5%), weight loss (1.2%), emotional lability (1%), and depression (0.7%). Over half of
these patients were exposed to ADDERALL XR for 12 months or more.
In a separate placebo-controlled 4 week study in adolescents with ADHD, five patients (2.1%)
discontinued treatment due to adverse events among ADDERALL XR-treated patients (N=233)
compared to none
who received placebo (N=54). The most frequent adverse event leading to
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 8 of 21
discontinuation and considered to be drug-related (i.e., leading to discontinuation in at least 1% of
ADDERALL XR-treated patients and at a rate at least twice that of placebo) was insomnia (1.3%,
n=3).
In one placebo-controlled 4 week study among adults with ADHD with doses 20 to 60 mg, 23 patients
(12.0%) discontinued treatment due to adverse events among ADDERALL XR-treated patients
(N=191) compared to one patient (1.6%) who received placebo (N=64). The most frequent adverse
events leading to discontinuation and considered to be drug-related (i.e., leading to discontinuation in
at least 1% of ADDERALL XR-treated patients and at a rate at least twice that of placebo) were
insomnia (5.2%, n=10), anxiety (2.1%, n=4), nervousness (1.6%, n=3), dry mouth (1.6%, n=3),
anorexia (1.6%, n=3), tachycardia (1.6%, n=3), headache (1.6%, n=3), and asthenia (1.0%, n=2).
Adverse Reactions Occurring in Controlled Trials
Adverse reactions reported in a 3 week clinical trial of children and a 4 week clinical trial in
adolescents and adults, respectively, treated with ADDERALL XR or placebo are presented in the
tables below.
Table 1: Adverse Reactions Reported by 2% or More of Children (6 to 12 Years Old) Receiving
ADDERALL XR with Higher Incidence Than on Placebo in a 584 Patient Clinical Study
Body System
Preferred Term
ADDERALL XR
(n=374)
Placebo
(n=210)
General
Abdominal Pain
(stomachache)
Fever
Infection
Accidental Injury
Asthenia (fatigue)
14%
5%
4%
3%
2%
10%
2%
2%
2%
0%
Digestive System
Loss of Appetite
Vomiting
Nausea
Dyspepsia
22%
7%
5%
2%
2%
4%
3%
1%
Nervous System
Insomnia
Emotional Lability
Nervousness
Dizziness
17%
9%
6%
2%
2%
2%
2%
0%
Metabolic/Nutritional
Weight Loss
4%
0%
Table 2: Adverse Reactions Reported by 5% or More of Adolescents (13 to 17 Years Old)
Weighing ≤75 kg/165 lbs Receiving ADDERALL XR with Higher Incidence Than Placebo in a
287 Patient Clinical Forced Weekly-Dose Titration Study*
Body System
Preferred Term
ADDERALL XR
(n=233)
Placebo
(n=54)
General
Abdominal Pain
(stomachache)
11%
2%
Digestive System
Loss of Appetite
b
36%
2%
Nervous System
Insomnia
b
Nervousness
12%
6%
4%
6%
a
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 9 of 21
Metabolic/Nutritional
Weight Loss
b
9%
0%
Note: The following reactions did not meet the criterion for inclusion in Table 2 but were reported by 2 to 4%
of adolescent patients receiving ADDERALL XR with a higher incidence than patients receiving
placebo in this study: accidental injury, asthenia (fatigue), dry mouth, dyspepsia, emotional lability,
nausea, somnolence, and vomiting.
* Included doses up to 40 mg.
a
Appears the same due to rounding.
b
Dose-related adverse reactions.
Table 3: Adverse Reactions Reported by 5% or More of Adults Receiving ADDERALL XR with
Higher Incidence Than on Placebo in a 255 Patient Clinical Forced Weekly-Dose Titration
Study*
Body System
Preferred Term
ADDERALL XR
(n=191)
Placebo
(n=64)
General
Headache
Asthenia
26%
6%
13%
5%
Digestive System
Dry Mouth
Loss of Appetite
Nausea
Diarrhea
35%
33%
8%
6%
5%
3%
3%
0%
Nervous System
Insomnia
Agitation
Anxiety
Dizziness
Nervousness
27%
8%
8%
7%
13%
13%
5%
5%
0%
13%
a
Cardiovascular System
Tachycardia
6%
3%
Metabolic/Nutritional
Weight Loss
10%
0%
Urogenital System
Urinary Tract Infection
5%
0%
Note: The following reactions did not meet the criterion for inclusion in Table 3 but were reported by 2 to 4%
of adult patients receiving ADDERALL XR with a higher incidence than patients receiving placebo in
this study: infection, photosensitivity reaction, constipation, tooth disorder (e.g., teeth clenching, tooth
infection), emotional lability, libido decreased, somnolence, speech disorder (e.g., stuttering,
excessive speech), palpitation, twitching, dyspnea, sweating, dysmenorrhea, and impotence.
* Included doses up to 60 mg.
a
Appears the same due to rounding.
Hypertension
In a controlled 4 week outpatient clinical study of adolescents with ADHD, isolated systolic blood
pressure elevations ≥15 mmHg were observed in 7/64 (11%) placebo-treated patients and 7/100
(7%) patients receiving ADDERALL XR 10 or 20 mg. Isolated elevations in diastolic blood pressure
≥8 mmHg were observed in 16/64 (25%) placebo-treated patients and 22/100 (22%) ADDERALL XR-
treated patients. Similar results were observed at higher doses [see Warnings and Precautions (5.2)].
In a single-dose pharmacokinetic study in 23 adolescents with ADHD, isolated increases in systolic
blood pressure (above the upper 95% CI for age, gender, and stature) were observed in 2/17 (12%)
and 8/23 (35%), subjects administered 10 and 20 mg ADDERALL XR, respectively. Higher single
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 10 of 21
doses were associated with a greater increase in systolic blood pressure. All increases were
transient, appeared maximal at 2 to 4 hours postdose and, not associated with symptoms.
6.2 Adverse Reactions Associated with the Use of Amphetamine, ADDERALL XR, or Adderall
The following adverse reactions have been identified during postapproval use of amphetamine,
ADDERALL XR, or Adderall. Because these reactions are reported voluntarily from a population of
uncertain size, it is not always possible to reliably estimate their frequency or establish a causal
relationship to drug exposure.
Allergic: Urticaria, rash, hypersensitivity reactions including angioedema and anaphylaxis. Serious
skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been
reported.
Cardiovascular: Palpitations. There have been isolated reports of cardiomyopathy associated with
chronic amphetamine use.
Central Nervous System: Psychotic episodes at recommended doses, overstimulation, restlessness,
irritability, euphoria, dyskinesia, dysphoria, depression, tremor, motor and verbal tics, aggression,
anger, logorrhea, dermatillomania, paresthesia (including formication), and bruxism.
Endocrine: Impotence, changes in libido, frequent or prolonged erections.
Eye Disorders: Vision blurred, mydriasis.
Gastrointestinal: Unpleasant taste, constipation, intestinal ischemia, and other gastrointestinal
disturbances.
Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis.
Skin: Alopecia.
Vascular Disorders: Raynaud’s phenomenon.
7 DRUG INTERACTIONS
7.1 Clinically Important Interactions with Amphetamines
Table 4: Drugs Having Clinically Important Interactions with Amphetamines
Monoamine Oxidase Inhibitors (MAOIs)
Clinical Impact
Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis.
Potential outcomes include death, stroke, myocardial infarction, aortic
dissection, ophthalmological complications, eclampsia, pulmonary edema, and
renal failure.
Intervention
Do not administer ADDERALL XR concomitantly or within 14 days after
discontinuing MAOI [see Contraindications (4)].
Serotonergic Drugs
Clinical Impact
The concomitant use of ADDERALL XR and serotonergic drugs increases the
risk of serotonin syndrome.
Intervention
Initiate with lower doses and monitor patients for signs and symptoms of
serotonin syndrome, particularly during ADDERALL XR initiation or dosage
increase. If serotonin syndrome occurs, discontinue ADDERALL XR and the
concomitant serotonergic drug(s) [see Warnings and Precautions (5.8)].
CYP2D6 Inhibitors
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 11 of 21
Clinical Impact
The concomitant use of ADDERALL XR and CYP2D6 inhibitors may increase
the exposure of ADDERALL XR compared to the use of the drug alone and
increase the risk of serotonin syndrome.
Intervention
Initiate with lower doses and monitor patients for signs and symptoms of
serotonin syndrome particularly during ADDERALL XR initiation and after a
dosage increase. If serotonin syndrome occurs, discontinue ADDERALL XR
and the CYP2D6 inhibitor [see Warnings and Precautions (5.8), Overdosage
(10)].
Alkalinizing Agents
Clinical Impact
Increase blood levels and potentiate the action of amphetamine.
Intervention
Coadministration of ADDERALL XR and gastrointestinal or urinary alkalinizing
agents should be avoided.
Acidifying Agents
Clinical Impact
Lower blood levels and efficacy of amphetamines.
Intervention
Increase dose based on clinical response.
Tricyclic Antidepressants
Clinical Impact
May enhance the activity of tricyclic or sympathomimetic agents causing striking
and sustained increases in the concentration of d-amphetamine in the brain;
cardiovascular effects can be potentiated.
Intervention
Monitor frequently and adjust or use alternative therapy based on clinical
response.
Proton Pump Inhibitors
Clinical Impact
Time to maximum concentration (T
max
) of amphetamine is decreased compared
to when administered alone.
Intervention
Monitor patients for changes in clinical effect and adjust therapy based on
clinical response.
7.2 Drug-Laboratory Test Interactions
Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is
greatest in the evening. Amphetamines may interfere with urinary steroid determinations.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to
ADDERALL XR during pregnancy. Healthcare providers are encouraged to register patients by calling
the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at
https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.
Risk Summary
Available data from published epidemiologic studies and postmarketing reports on use of prescription
amphetamine in pregnant women have not identified a drug-associated risk of major birth defects and
miscarriage (see Data). Adverse pregnancy outcomes, including premature delivery and low birth
weight, have been seen in infants born to mothers taking amphetamines during pregnancy (see
Clinical Considerations).
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 12 of 21
No apparent effects on morphological development were observed in embryo-fetal development
studies, with oral administration of amphetamine to rats and rabbits during organogenesis at doses
2 and 12 times, respectively, the maximum recommended human dose (MRHD) of 20 mg/day given
to adolescents, on a mg/m
2
basis. However, in a pre- and postnatal development study,
amphetamine (d- to l- ratio of 3:1) administered orally to pregnant rats during gestation and lactation
caused a decrease in pup survival and a decrease in pup body weight that correlated with a delay in
developmental landmarks at clinically relevant doses of amphetamine. In addition, adverse effects on
reproductive performance were observed in pups whose mothers were treated with amphetamine.
Long-term neurochemical and behavioral effects have also been reported in animal developmental
studies using clinically relevant doses of amphetamine (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is
unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In
the U.S. general population, the estimated background risk of major birth defects and miscarriage in
clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations
Fetal/Neonatal Adverse Reactions
Amphetamines, such as ADDERALL XR, cause vasoconstriction and thereby may decrease placental
perfusion. In addition, amphetamines can stimulate uterine contractions, increasing the risk of
premature delivery. Infants born to mothers taking amphetamines during pregnancy have an
increased risk of premature delivery and low birth weight.
Monitor infants born to mothers taking amphetamines for symptoms of withdrawal such as feeding
difficulties, irritability, agitation, and excessive drowsiness.
Data
Animal Data
Amphetamine (d- to l- enantiomer ratio of 3:1) had no apparent effects on embryofetal morphological
development or survival when administered orally to pregnant rats and rabbits throughout the period
of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately
2 and 12 times, respectively, the maximum recommended human dose (MRHD) of 20 mg/day given
to adolescents, on a mg/m
2
basis. Fetal malformations and death have been reported in mice
following parenteral administration of d-amphetamine doses of 50 mg/kg/day (approximately 10 times
the MRHD given to adolescents on a mg/m
2
basis) or greater to pregnant animals. Administration of
these doses was also associated with severe maternal toxicity.
A study was conducted in which pregnant rats received daily oral doses of amphetamine (d- to l-
enantiomer ratio of 3:1) of 2, 6, and 10 mg/kg from gestation Day 6 to lactation Day 20. These doses
are approximately 0.8, 2, and 4 times the MRHD of 20 mg/day given to adolescents, on a mg/m
2
basis. All doses caused hyperactivity and decreased weight gain in the dams. A decrease in pup
survival was seen at all doses. A decrease in pup body weight was seen at 6 and 10 mg/kg which
correlated with delays in developmental landmarks, such as preputial separation and vaginal opening.
Increased pup locomotor activity was seen at 10 mg/kg on Day 22 postpartum but not at 5 weeks
postweaning. When pups were tested for reproductive performance at maturation, gestational weight
gain, number of implantations, and number of delivered pups were decreased in the group whose
mothers had been given 10 mg/kg.
A number of studies from the literature in rodents indicate that prenatal or early postnatal exposure to
amphetamine (d- or d, l-) at doses similar to those used clinically can result in long-term
neurochemical and behavioral alterations. Reported behavioral effects include learning and memory
deficits, altered locomotor activity, and changes in sexual function.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 13 of 21
8.2 Lactation
Risk Summary
Based on limited case reports in published literature, amphetamine (d- or d, l-) is present in human
milk, at relative infant doses of 2 to 13.8% of the maternal weight-adjusted dosage and a milk/plasma
ratio ranging between 1.9 and 7.5. There are no reports of adverse effects on the breastfed infant.
Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is
possible that large dosages of amphetamine might interfere with milk production, especially in women
whose lactation is not well established. Because of the potential for serious adverse reactions in
nursing infants, advise patients that breastfeeding is not recommended during treatment with
ADDERALL XR.
8.4 Pediatric Use
The safety and effectiveness of ADDERALL XR have been established in pediatric patients with
ADHD 6 years of age and older.
The safety and efficacy of ADDERALL XR in pediatric patients less than 6 years of age have not
been established. Long-term effects of amphetamines in pediatric patients has not been well
established.
Long-Term Growth Suppression
Growth should be monitored during treatment with stimulants, including ADDERALL XR, and pediatric
patients aged 6 to 17 years who are not growing or gaining weight as expected may need to have
their treatment interrupted [see Warnings and Precautions (5.5)].
Juvenile Animal Toxicity Data
Juvenile rats treated with mixed amphetamine salts early in the postnatal period through sexual
maturation demonstrated transient changes in motor activity. Learning and memory was impaired at
approximately 6 times the maximum recommended human dose (MRHD) given to children on a
mg/m
2
basis. No recovery was seen following a drug-free period. A delay in sexual maturation was
observed at a dose approximately 6 times the MRHD given to children on a mg/m
2
basis, although
there was no effect on fertility.
In a juvenile developmental study, rats received daily oral doses of amphetamine (d to l enantiomer
ratio of 3:1) of 2, 6, or 20 mg/kg on Days 7 to 13 of age; from Day 14 to approximately Day 60 of age
these doses were given b.i.d. for total daily doses of 4, 12, or 40 mg/kg. The latter doses are
approximately 0.6, 2, and 6 times the MRHD of 30 mg/day, given to children on a mg/m
2
basis.
Postdosing hyperactivity was seen at all doses; motor activity measured prior to the daily dose was
decreased during the dosing period but the decreased motor activity was largely absent after an
18 day drug-free recovery period. Performance in the Morris water maze test for learning and
memory was impaired at the 40 mg/kg dose, and sporadically at the lower doses, when measured
prior to the daily dose during the treatment period; no recovery was seen after a 19 day drug-free
period. A delay in the developmental milestones of vaginal opening and preputial separation was
seen at 40 mg/kg but there was no effect on fertility.
8.5 Geriatric Use
ADDERALL XR has not been studied in the geriatric population.
8.6 Renal Impairment
Due to reduced clearance of amphetamines in patients with severe renal impairment (GFR 15 to
<30 mL/min/1.73 m
2
), the recommended dose should be reduced. ADDERALL XR is not
recommended in patients with ESRD (GFR <15 mL/min/1.73 m
2
) [see Dosage and Administration
(2.6), Clinical Pharmacology (12.3)].
d-Amphetamine is not dialyzable.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 14 of 21
9 DRUG ABUSE AND DEPENDENCE
9.1 Controlled Substance
ADDERALL XR contains amphetamine, a Schedule II controlled substance.
9.2 Abuse
ADDERALL XR has a high potential for abuse and misuse which can lead to the development of a
substance use disorder, including addiction [see Warnings and Precautions (5.1)]. ADDERALL XR
can be diverted for non-medical use into illicit channels or distribution.
Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological
or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an
individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed.
Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a
strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite
harmful consequences, giving a higher priority to drug use than other activities and obligations), and
possible tolerance or physical dependence.
Misuse and abuse of amphetamine may cause increased heart rate, respiratory rate, or blood
pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of
coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility,
aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse
and/or misuse. Misuse and abuse of CNS stimulants, including ADDERALL XR, can result in
overdose and death [see Overdosage (10)], and this risk is increased with higher doses or
unapproved methods of administration, such as snorting or injection.
9.3 Dependence
Physical Dependence
ADDERALL XR may produce physical dependence. Physical dependence is a state that develops as
a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs
and symptoms after abrupt discontinuation or a significant dose reduction of a drug.
Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged
use of CNS stimulants including ADDERALL XR include dysphoric mood; depression; fatigue; vivid,
unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or
agitation.
Tolerance
ADDERALL XR may produce tolerance. Tolerance is a physiological state characterized by a
reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to
produce the same effect that was once obtained at a lower dose).
10 OVERDOSAGE
Clinical Effects of Overdose
Overdose of CNS stimulants is characterized by the following sympathomimetic effects:
• Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension.
Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death.
Takotsubo cardiomyopathy may develop.
• CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin
syndrome, seizures, cerebral vascular accidents, and coma may occur.
• Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may
develop.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 15 of 21
Overdose Management
Consider the possibility of multiple drug ingestion. The pharmacokinetic profile of ADDERALL XR
should be considered when treating patients with overdose. D-amphetamine is not dialyzable.
Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional
overdose management recommendations.
11 DESCRIPTION
ADDERALL XR extended-release capsules contain mixed salts of a single-entity amphetamine, a
CNS stimulant. ADDERALL XR contains equal amounts (by weight) of four salts: dextroamphetamine
sulfate, amphetamine sulfate, dextroamphetamine saccharate and amphetamine (D, L)-aspartate
monohydrate. This results in a 3.1:1 mixture of dextro- to levo-amphetamine base equivalent.
The 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg strength extended-release capsules are for oral
administration. ADDERALL XR contains two types of drug-containing beads (immediate-release and
delayed-release) which prolong the release of amphetamine compared to the Adderall (immediate-
release) tablet formulation.
Each capsule contains:
Capsule Strength 5 mg 10 mg 15 mg 20 mg 25 mg 30 mg
Dextroamphetamine Saccharate 1.25 mg 2.5 mg 3.75 mg 5.0 mg 6.25 mg 7.5 mg
Amphetamine (D,L)-Aspartate Monohydrate 1.25 mg 2.5 mg 3.75 mg 5.0 mg 6.25 mg 7.5 mg
Dextroamphetamine Sulfate 1.25 mg 2.5 mg 3.75 mg 5.0 mg 6.25 mg 7.5 mg
Amphetamine Sulfate 1.25 mg 2.5 mg 3.75 mg 5.0 mg 6.25 mg 7.5 mg
Total amphetamine base equivalence 3.1 mg 6.3 mg 9.4 mg 12.5 mg 15.6 mg 18.8 mg
d-amphetamine base equivalence 2.4 mg 4.7 mg 7.1 mg 9.5 mg 11.9 mg 14.2 mg
l-amphetamine base equivalence 0.75 mg 1.5 mg 2.3 mg 3.0 mg 3.8 mg 4.5 mg
Inactive Ingredients and Colors
The inactive ingredients in ADDERALL XR extended-release capsules include: gelatin capsules,
hydroxypropyl methylcellulose, methacrylic acid copolymer, opadry beige, sugar spheres, talc, and
triethyl citrate. Gelatin capsules contain edible inks, kosher gelatin, and titanium dioxide. The 5, 10,
and 15 mg capsules also contain FD&C Blue #2. The 20 mg, 25 mg, and 30 mg capsules also
contain red iron oxide and yellow iron oxide.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The
mode of therapeutic action in ADHD is not known.
12.2 Pharmacodynamics
Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and
increase the release of these monoamines into the extraneuronal space.
12.3 Pharmacokinetics
Pharmacokinetic studies of ADDERALL XR have been conducted in healthy adult and pediatric
(children aged 6 to 12 yrs) subjects, adolescent (13 to 17 yrs), and children with ADHD. Both Adderall
(immediate-release) tablets and ADDERALL XR extended-release capsules contain d-amphetamine
and l-amphetamine salts in the ratio of 3:1. Following administration of Adderall (immediate-release),
the peak plasma concentrations occurred in about 3 hours for both d-amphetamine and l-
amphetamine.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 16 of 21
The time to reach maximum plasma concentration (T
max
) for ADDERALL XR is about 7 hours, which
is about 4 hours longer compared to Adderall
(immediate-release). This is consistent with the
extended-release nature of the product.
Figure 1: Mean d-amphetamine and l-amphetamine Plasma Concentrations Following
Administration of ADDERALL XR 20 mg (8 am) and Adderall
(immediate-release)
10 mg Twice Daily (8 am and 12 noon) in the Fed State.
A single dose of ADDERALL XR 20 mg extended-release capsules provided comparable plasma
concentration profiles of both d-amphetamine and l-amphetamine to Adderall
(immediate-release)
10 mg twice daily administered 4 hours apart.
The mean elimination half-life for d-amphetamine is 10 hours in adults; 11 hours in adolescents aged
13 to 17 years and weighing less than or equal to 75 kg/165 lbs; and 9 hours in children aged 6 to
12 years. For the l-amphetamine, the mean elimination half-life in adults is 13 hours; 13 to 14 hours in
adolescents; and 11 hours in children aged 6 to 12 years. On a mg/kg body weight basis, children
have a higher clearance than adolescents or adults (see Special Populations below).
ADDERALL XR demonstrates linear pharmacokinetics over the dose range of 20 to 60 mg in adults
and adolescents weighing greater than 75 kg/165 lbs, over the dose range of 10 to 40 mg in
adolescents weighing less than or equal to 75 kg/165 lbs, and 5 to 30 mg in children aged 6 to
12 years. There is no unexpected accumulation at steady state in children.
Food does not affect the extent of absorption of d-amphetamine and l-amphetamine, but prolongs
T
max
by 2.5 hours (from 5.2 hrs at fasted state to 7.7 hrs after a high-fat meal) for d-amphetamine and
2.7 hours (from 5.6 hrs at fasted state to 8.3 hrs after a high-fat meal) for l-amphetamine after
administration of ADDERALL XR 30 mg. Opening the capsule and sprinkling the contents on
0
4
8
12
16
20
24
0
5
10
15
20
25
30
ADDERALL XR
®
20 mg qd
ADDERALL
®
10 mg bid
ADDERALL XR
®
20 mg qd
ADDERALL
®
10 mg bid
DEXTROAMPHETAMINE
LEVOAMPHETAMINE
TIME (HOURS)
MEAN PLASMA CONCENTRATIONS OF DEXTRO AND LEVOAMPHETAMINE (ng/mL)
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 17 of 21
applesauce results in comparable absorption to the intact capsule taken in the fasted state. Equal
doses of ADDERALL XR strengths are bioequivalent.
Metabolism and Excretion
Amphetamine is reported to be oxidized at the 4 position of the benzene ring to form 4-
hydroxyamphetamine, or on the side chain α or β carbons to form alpha-hydroxy-amphetamine or
norephedrine, respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is
subsequently oxidized to form 4-hydroxy-norephedrine. Alpha-hydroxy-amphetamine undergoes
deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the
glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not
been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine.
Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a
possibility.
Amphetamine is known to inhibit monoamine oxidase, whereas the ability of amphetamine and its
metabolites to inhibit various P450 isozymes and other enzymes has not been adequately elucidated.
In vitro experiments with human microsomes indicate minor inhibition of CYP2D6 by amphetamine
and minor inhibition of CYP1A2, 2D6, and 3A4 by one or more metabolites. However, due to the
probability of auto-inhibition and the lack of information on the concentration of these metabolites
relative to in vivo concentrations, no predications regarding the potential for amphetamine or its
metabolites to inhibit the metabolism of other drugs by CYP isozymes in vivo can be made.
With normal urine pHs, approximately half of an administered dose of amphetamine is recoverable in
urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30 to 40% of the dose
is recoverable in urine as amphetamine itself. Since amphetamine has a pKa of 9.9, urinary recovery
of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less
ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal
elimination with clearances greater than glomerular filtration rates, indicating the involvement of active
secretion. Urinary recovery of amphetamine has been reported to range from 1 to 75%, depending on
urinary pH, with the remaining fraction of the dose hepatically metabolized. Consequently, both
hepatic and renal dysfunction have the potential to inhibit the elimination of amphetamine and result
in prolonged exposures. In addition, drugs that effect urinary pH are known to alter the elimination of
amphetamine, and any decrease in amphetamine’s metabolism that might occur due to drug
interactions or genetic polymorphisms is more likely to be clinically significant when renal elimination
is decreased [see Drug Interactions (7)].
Special Populations
Comparison of the pharmacokinetics of d- and l-amphetamine after oral administration of ADDERALL
XR in children (6 to 12 years) and adolescent (13 to 17 years) ADHD patients and healthy adult
volunteers indicates that body weight is the primary determinant of apparent differences in the
pharmacokinetics of d- and l-amphetamine across the age range. Systemic exposure measured by
area under the curve to infinity (AUC
) and maximum plasma concentration (C
max
) decreased with
increases in body weight, while oral volume of distribution (V
Z
/F), oral clearance (CL/F), and
elimination half-life (t
1/2
) increased with increases in body weight.
Pediatric Patients
On a mg/kg weight basis, children eliminated amphetamine faster than adults. The elimination half-life
(t
1/2
) is approximately 1 hour shorter for d-amphetamine and 2 hours shorter for l-amphetamine in
children than in adults. However, children had higher systemic exposure to amphetamine (C
max
and
AUC) than adults for a given dose of ADDERALL XR, which was attributed to the higher dose
administered to children on a mg/kg body weight basis compared to adults. Upon dose normalization
on a mg/kg basis, children showed 30% less systemic exposure compared to adults.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 18 of 21
Gender
Systemic exposure to amphetamine was 20 to 30% higher in women (N=20) than in men (N=20) due
to the higher dose administered to women on a mg/kg body weight basis. When the exposure
parameters (C
max
and AUC) were normalized by dose (mg/kg), these differences diminished. Age and
gender had no direct effect on the pharmacokinetics of d- and l-amphetamine.
Race
Formal pharmacokinetic studies for race have not been conducted. However, amphetamine
pharmacokinetics appeared to be comparable among Caucasians (N=33), Blacks (N=8), and
Hispanics (N=10).
Patients with Renal Impairment
The effect of renal impairment on d- and l-amphetamine after administration of ADDERALL XR has
not been studied. The impact of renal impairment on the disposition of amphetamine is expected to
be similar between oral administration of lisdexamfetamine and ADDERALL XR.
In a pharmacokinetic study of lisdexamfetamine in adult subjects with normal and impaired renal
function, mean d-amphetamine clearance was reduced from 0.7 L/hr/kg in normal subjects to
0.4 L/hr/kg in subjects with severe renal impairment (GFR 15 to <30 mL/min/1.73 m
2
). Dialysis did not
significantly affect the clearance of d-amphetamine [see Use in Specific Populations (8.6)].
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
No evidence of carcinogenicity was found in studies in which d, l-amphetamine (enantiomer ratio of
1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male
mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are
approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of
30 mg/day given to children, on a mg/m
2
basis.
Mutagenesis
Amphetamine, in the enantiomer ratio d- to l- ratio of 3:1, was not clastogenic in the mouse bone
marrow micronucleus test in vivo and was negative when tested in the E. coli component of the Ames
test in vitro. d, l-Amphetamine (1:1 enantiomer ratio) has been reported to produce a positive
response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and
negative responses in the in vitro sister chromatid exchange and chromosomal aberration assays.
Impairment of Fertility
Amphetamine, in the enantiomer ratio d- to l- ratio of 3:1, did not adversely affect fertility or early
embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 8 times the
maximum recommended human dose of 20 mg/day given to adolescents, on a mg/m
2
basis).
13.2 Animal Toxicology and/or Pharmacology
Acute administration of high doses of amphetamine (d- or d, l-) has been shown to produce long-
lasting neurotoxic effects, including irreversible nerve fiber damage in rodents. The significance of
these findings to humans is unknown.
14 CLINICAL STUDIES
Pediatric Patients
A double-blind, randomized, placebo-controlled, parallel-group study was conducted in children aged
6 to 12 (N=584) who met DSM-IV
®
criteria for ADHD (either the combined type or the hyperactive-
impulsive type). Patients were randomized to fixed-dose treatment groups receiving final doses of 10,
20, or 30 mg of ADDERALL XR or placebo once daily in the morning for three weeks. Significant
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 19 of 21
improvements in patient behavior, based upon teacher ratings of attention and hyperactivity, were
observed for all ADDERALL XR doses compared to patients who received placebo, for all three
weeks, including the first week of treatment, when all ADDERALL XR subjects were receiving a dose
of 10 mg/day. Patients who received ADDERALL XR showed behavioral improvements in both
morning and afternoon assessments compared to patients on placebo.
In a classroom analogue study, patients (N=51) receiving fixed doses of 10, 20, or 30 mg ADDERALL
XR demonstrated statistically significant improvements in teacher-rated behavior and performance
measures, compared to patients treated with placebo.
A double-blind, randomized, multicenter, parallel-group, placebo-controlled study was conducted in
adolescents aged 13 to 17 (N=327) who met DSM-IV
®
criteria for ADHD. The primary cohort of
patients (n=287, weighing ≤75 kg/165 lbs) were randomized to fixed-dose treatment groups and
received four weeks of treatment. Patients were randomized to receive final doses of 10, 20, 30, and
40 mg ADDERALL XR or placebo once daily in the morning. Patients randomized to doses greater
than 10 mg were titrated to their final doses by 10 mg each week. The secondary cohort consisted of
40 subjects weighing >75 kg/165 lbs who were randomized to fixed-dose treatment groups receiving
final doses of 50 and 60 mg ADDERALL XR or placebo once daily in the morning for 4 weeks. The
primary efficacy variable was the Attention Deficit Hyperactivity Disorder-Rating Scale IV
(ADHD-RS-
IV) total score for the primary cohort. The ADHD-RS-IV is an 18-item scale that measures the core
symptoms of ADHD. Improvements in the primary cohort were statistically significantly greater in all
four primary cohort active treatment groups (ADDERALL XR 10 mg, 20 mg, 30 mg, and 40 mg)
compared with the placebo group. There was not adequate evidence that doses greater than
20 mg/day conferred additional benefit.
Adult Patients
A double-blind, randomized, placebo-controlled, parallel-group study was conducted in adults
(N=255) who met DSM-IV
®
criteria for ADHD. Patients were randomized to fixed-dose treatment
groups receiving final doses of 20, 40, or 60 mg of ADDERALL XR or placebo once daily in the
morning for four weeks. Significant improvements, measured with the Attention Deficit Hyperactivity
Disorder-Rating Scale (ADHD-RS), an 18-item scale that measures the core symptoms of ADHD,
were observed at endpoint for all ADDERALL XR doses compared to patients who received placebo
for all four weeks. There was not adequate evidence that doses greater than 20 mg/day conferred
additional benefit.
16 HOW SUPPLIED/STORAGE AND HANDLING
ADDERALL XR
5 mg extended-release capsules: Clear/blue (imprinted ADDERALL XR 5 mg), bottles
of 100, NDC 54092-381-01
ADDERALL XR
10 mg extended-release capsules: Blue/blue (imprinted ADDERALL XR 10 mg),
bottles of 100, NDC 54092-383-01
ADDERALL XR
15 mg extended-release capsules: Blue/white (imprinted ADDERALL XR 15 mg),
bottles of 100, NDC 54092-385-01
ADDERALL XR
20 mg extended-release capsules: Orange/orange (imprinted ADDERALL XR
20 mg), bottles of 100, NDC 54092-387-01
ADDERALL XR
25 mg extended-release capsules: Orange/white (imprinted ADDERALL XR 25 mg),
bottles of 100, NDC 54092-389-01
ADDERALL XR
30 mg extended-release capsules: Natural/orange (imprinted ADDERALL XR 30 mg),
bottles of 100, NDC 54092-391-01
Dispense in a tight, light-resistant container as defined in the USP.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 20 of 21
Store at room temperature, 20 to 25ºC (68 to 77ºF). Excursions permitted to 15 to 30ºC (59 to 86ºF)
[see USP Controlled Room Temperature].
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Abuse, Misuse, and Addiction
Educate patients and their families about the risks of abuse, misuse, and addiction of ADDERALL
XR, which can lead to overdose and death, and proper disposal of any unused drug [see Warnings
and Precautions (5.1), Drug Abuse and Dependence (9.2), Overdosage (10)]. Advise patients to store
ADDERALL XR in a safe place, preferably locked, and instruct patients to not give ADDERALL XR to
anyone else.
Risks to Patients with Serious Cardiac Disease
Advise patients that there are potential risks to patients with serious cardiac disease, including
sudden death, with ADDERALL XR use. Instruct patients to contact a healthcare provider
immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other
symptoms suggestive of cardiac disease [see Warnings and Precautions (5.2)].
Increased Blood Pressure and Heart Rate
Advise patients that ADDERALL XR can cause elevations in blood pressure and heart rate [see
Warnings and Precautions (5.3)].
Psychiatric Adverse Reactions
Prior to initiating treatment with ADDERALL XR, adequately screen patients with comorbid
depressive symptoms to determine if they are at risk for bipolar disorder. Such screening should
include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and/or
depression. Additionally, ADDERALL XR therapy at usual doses may cause treatment-emergent
psychotic or manic symptoms in patients without prior history of psychotic symptoms or mania [see
Warnings and Precautions (5.4)].
Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaud’s
Phenomenon]
Instruct patients beginning treatment with ADDERALL XR about the risk of peripheral vasculopathy,
including Raynaud’s phenomenon, and in associated signs and symptoms: fingers or toes may feel
numb, cool, painful, and/or may change color from pale, to blue, to red. Instruct patients to report to
their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or
toes. Instruct patients to call their physician immediately with any signs of unexplained wounds
appearing on fingers or toes while taking ADDERALL XR. Further clinical evaluation (e.g.,
rheumatology referral) may be appropriate for certain patients [see Warnings and Precautions (5.7)].
Serotonin Syndrome
Caution patients about the risk of serotonin syndrome with concomitant use of ADDERALL XR and
other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium,
tramadol, tryptophan, buspirone, St. John’s Wort, and with drugs that impair metabolism of serotonin
(in particular MAOIs, both those intended to treat psychiatric disorders and also others such as
linezolid) [see Contraindications (4), Warnings and Precautions (5.8), Drug Interactions (7.1)]. Advise
patients to contact their healthcare provider or report to the emergency room if they experience signs
or symptoms of serotonin syndrome.
Concomitant Medications
Advise patients to notify their physicians if they are taking, or plan to take, any prescription or over-
the-counter drugs because there is a potential for interactions [see Drug Interactions (7.1)].
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 21 of 21
Growth
Monitor growth in children during treatment with ADDERALL XR, and patients who are not growing or
gaining weight as expected may need to have their treatment interrupted [see Warnings and
Precautions (5.5)].
Motor and Verbal Tics, and Worsening of Tourette’s Syndrome
Advise patients that motor and verbal tics and worsening of Tourette’s syndrome may occur during
treatment with ADDERALL XR. Instruct patients to notify their healthcare provider if emergence of
new tics or worsening of tics or Tourette’s syndrome occurs [see Warnings and Precautions (5.9)].
Pregnancy Registry
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in
women exposed to ADDERALL XR during pregnancy [see Use in Specific Populations (8.1)].
Pregnancy
Advise patients to notify their healthcare provider if they become pregnant or intend to become
pregnant during treatment with ADDERALL XR. Advise patients of the potential fetal effects from the
use of ADDERALL XR during pregnancy [see Use in Specific Populations (8.1)].
Lactation
Advise women not to breastfeed if they are taking ADDERALL XR [see Use in Specific Populations
(8.2)].
Distributed by:
Takeda Pharmaceuticals America, Inc.
Lexington, MA 02421
Made in USA.
For more information call 1-800-828-2088
ADDERALL XR
®
is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc.
ADDERALL
®
is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc. under license to
Duramed Pharmaceuticals, Inc.
© 202x Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.
ADL364
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 1 of 4
MEDICATION GUIDE
ADDERALL XR
®
(ADD-ur-all X-R)
(mixed salts of a single-entity amphetamine product)
extended-release capsules, CII
What is the most important information I should know about ADDERALL XR?
ADDERALL XR may cause serious side effects, including:
• Abuse, misuse, and addiction. ADDERALL XR has a high chance for abuse and misuse and may lead to
substance use problems, including addiction. Misuse and abuse of ADDERALL XR, other amphetamine containing
medicines, and methylphenidate containing medicines, can lead to overdose and death. The risk of overdose and
death is increased with higher doses of ADDERALL XR or when it is used in ways that are not approved, such as
snorting or injection.
o Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting
treatment with ADDERALL XR and will monitor you or your child during treatment.
o ADDERALL XR may lead to physical dependence after prolonged use, even if taken as directed by your
healthcare provider.
o Do not give ADDERALL XR to anyone else. See “What is ADDERALL XR?” for more information.
o Keep ADDERALL XR in a safe place and properly dispose of any unused medicine. See “How should I store
ADDERALL XR?” for more information.
Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription
medicines, or street drugs.
• Risks for people with serious heart disease. Sudden death has happened in people who have heart defects or
other serious heart disease.
Your healthcare provider should check you or your child carefully for heart problems before starting treatment with
ADDERALL XR. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart
defects.
Call your healthcare provider or go to the nearest hospital emergency room right away if you or your child
have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with
ADDERALL XR.
• Increased blood pressure and heart rate.
Your healthcare provider should check you or your child’s blood pressure and heart rate regularly during treatment
with ADDERALL XR.
• Mental (psychiatric) problems, including:
o new or worse behavior or thought problems
o new or worse bipolar illness
o new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic
symptoms
Tell your healthcare provider about any mental problems you or your child have or about a family history of suicide,
bipolar illness, or depression.
Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or
problems during treatment with ADDERALL XR, especially hearing voices, seeing or believing things that are
not real, or new manic symptoms.
What is ADDERALL XR?
ADDERALL XR is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention
Deficit Hyperactivity Disorder (ADHD) in adults and children 6 years of age and older. ADDERALL XR may help
increase attention and decrease impulsiveness and hyperactivity in people with ADHD.
It is not known if ADDERALL XR is safe and effective in children under 6 years of age.
ADDERALL XR is a federally controlled substance (CII) because it contains amphetamine that can be a target
for people who abuse prescription medicines or street drugs. Keep ADDERALL XR in a safe place to protect it
from theft. Never give your ADDERALL XR to anyone else because it may cause death or harm them. Selling or giving
away ADDERALL XR may harm others and is against the law.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 2 of 4
Do not take ADDERALL XR if you or your child:
• are taking or have taken within the past 14 days, a medicine used to treat depression called a monoamine oxidase
inhibitor (MAOI), including the antibiotic linezolid or the intravenous medicine methylene blue
• are allergic to amphetamine products or any of the ingredients in ADDERALL XR. See the end of this Medication
Guide for a complete list of ingredients in ADDERALL XR.
Before taking ADDERALL XR tell your healthcare provider about all of your or your child’s medical conditions,
including if you or your child:
• have heart problems, heart disease, heart defects, or high blood pressure
• have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide,
bipolar illness, or depression
• have kidney problems
• have seizures or have had an abnormal brain wave test (EEG)
• have circulation problems in fingers and toes
• have or had repeated movements or sounds (tics) or Tourette’s syndrome, or have a family history of tics or
Tourette’s syndrome
• are pregnant or plan to become pregnant. It is not known if ADDERALL XR will harm the unborn baby. Tell your
healthcare provider if you or your child become pregnant during treatment with ADDERALL XR.
o There is a pregnancy registry for females who are exposed to ADDERALL XR during pregnancy. The
purpose of the registry is to collect information about the health of females exposed to ADDERALL XR and
their baby. If you or your child becomes pregnant during treatment with ADDERALL XR, talk to your
healthcare provider about registering with the National Pregnancy Registry of Psychostimulants at
1-866-961-2388 or visit online at https://womensmentalhealth.org/clinical-and-research-
programs/pregnancyregistry/othermedications/.
• are breastfeeding or plan to breastfeed. ADDERALL XR passes into breast milk. You or your child should not
breastfeed during treatment with ADDERALL XR. Talk to your healthcare provider about the best way to feed
the baby during treatment with ADDERALL XR.
Tell your healthcare provider about all of the medicines that you or your child take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements.
ADDERALL XR and some medicines may interact with each other and cause serious side effects. Sometimes the
doses of other medicines will need to be changed during treatment with ADDERALL XR.
Your healthcare provider will decide if ADDERALL XR can be taken with other medicines.
Especially tell your healthcare provider if you or your child take:
• selective serotonin reuptake inhibitors (SSRIs)
• serotonin norepinephrine reuptake inhibitors (SNRIs)
• medicines used to treat migraine headaches
called triptans
• lithium
• tramadol
• buspirone
• tricyclic antidepressants
• fentanyl
• tryptophan
• St. John’s Wort
Know the medicines that you or your child take. Keep a list of your or your child’s medicines with you to show your
healthcare provider and pharmacist when you or your child get a new medicine.
Do not start any new medicine during treatment with ADDERALL XR without talking to your healthcare
provider first.
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 3 of 4
How should ADDERALL XR be taken?
• Take ADDERALL XR exactly as prescribed by your or your child’s healthcare provider.
• Your healthcare provider may change the dose if needed.
• Take ADDERALL XR 1 time each day in the morning when you first wake up.
• ADDERALL XR can be taken with or without food.
• Swallow ADDERALL XR capsules whole. If you or your child cannot swallow the capsule whole, open it and
sprinkle the medicine on applesauce.
o Swallow all of the applesauce and medicine mixture right away.
o Do not chew the applesauce and medicine mixture.
o Do not store the applesauce sprinkled with ADDERALL XR.
If you or your child take too much ADDERALL XR, call your healthcare provider or Poison Help line at 1-800-222-1222
or go to the nearest hospital emergency room right away.
What are the possible side effects of ADDERALL XR?
ADDERALL XR may cause serious side effects, including:
• See “What is the most important information I should know about ADDERALL XR?”
• Slowing of growth (height and weight) in children. Children should have their height and weight checked often
during treatment with ADDERALL XR. Your healthcare provider may stop your child’s ADDERALL XR treatment if
they are not growing or gaining weight as expected.
• Seizures. Your healthcare provider may stop treatment with ADDERALL XR if you or your child have a seizure.
• Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon).
Signs and symptoms may include:
o fingers or toes may feel numb, cool, painful
o fingers or toes may change color from pale, to blue, to red
Tell your healthcare provider if you have or your child have any numbness, pain, skin color change, or sensitivity to
temperature in your fingers or toes.
Call your healthcare provider right away if you have or your child have any signs of unexplained wounds
appearing on fingers or toes during treatment with ADDERALL XR.
• Serotonin syndrome. This problem may happen when ADDERALL XR is taken with certain other medicines and
may be life-threatening. Stop taking ADDERALL XR and call your healthcare provider or go to the nearest hospital
emergency room right away if you or your child develop any of the following signs and symptoms of serotonin
syndrome:
o agitation, hallucinations, coma, or other
changes in mental status
o problems controlling movements or muscle
twitching
o fast heartbeat
o seizures
o loss of coordination
o confusion
o dizziness
o change in blood pressure
o sweating or fever
o nausea, vomiting, or diarrhea
o muscle stiffness or tightness
o high body temperature (hyperthermia)
• New or worsening tics or worsening Tourette’s Syndrome. Tell your healthcare provider if you or your child get
any new or worsening tics or worsening Tourette’s syndrome during treatment with ADDERALL XR.
The most common side effects of ADDERALL XR in children ages 6 to 12 include:
• loss of appetite
• trouble sleeping
• stomach (abdominal) pain
• mood swings
• vomiting
• nervousness
• nausea
• fever
The most common side effects of ADDERALL XR in adolescents ages 13 to 17 include:
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda
Page 4 of 4
• loss of appetite
• trouble sleeping
• stomach (abdominal pain)
• weight loss
• nervousness
The most common side effects of ADDERALL XR in adults include:
• dry mouth
• loss of appetite
• trouble sleeping
• headache
• weight loss
• nausea
• anxiety
• agitation
• dizziness
• fast heartbeat
• diarrhea
• weakness
• urinary tract infections (UTIs)
These are not all the possible side effects of ADDERALL XR.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ADDERALL XR
• Store ADDERALL XR at room temperature between 68 to 77°F (20 to 25°C).
• Protect ADDERALL XR from light.
• Store ADDERALL XR in a safe place, like a locked cabinet.
• Dispose of remaining, unused, or expired ADDERALL XR by a medicine take-back program at a U.S. Drug
Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is
available, mix ADDERALL XR with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee
grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic
bag and throw away ADDERALL XR in the household trash. Visit www.fda.gov/drugdisposal for additional
information on disposal of unused medicines.
Keep ADDERALL XR and all medicines out of the reach of children.
General information about the safe and effective use of ADDERALL XR.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use
ADDERALL XR for a condition for which it was not prescribed. Do not give ADDERALL XR to other people, even if they
have the same condition. It may harm them and it is against the law.
You can ask your healthcare provider or pharmacist for information about ADDERALL XR that is written for healthcare
professionals.
What are the ingredients in ADDERALL XR?
Active ingredient: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and
amphetamine aspartate monohydrate
Inactive Ingredients: gelatin capsules, hydroxypropyl methylcellulose, methacrylic acid copolymer, opadry beige,
sugar spheres, talc, and triethyl citrate. Gelatin capsules contain edible inks, kosher gelatin, and titanium dioxide. The
5 mg, 10 mg, and 15 mg capsules also contain FD&C Blue #2. The 20 mg, 25 mg, and 30 mg capsules also contain
red iron oxide and yellow iron oxide
Distributed by:
Takeda Pharmaceuticals America, Inc, Lexington, MA 02421
ADDERALL XR
®
is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc.
© 202x Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.
For more information, you may also contact Takeda Pharmaceuticals (the maker of ADDERALL XR) at 1-800-828-2088 or visit the website at
http://www.adderallxr.com.
This Medication Guide has been approved by the U.S. Food and Drug Administration. ADL364 Revised: 10/2023
Reference ID: 5260286
This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda